Gender disparities in the tumor genetics and clinical outcome of multiple myeloma
Boyd, Kevin D., Ross, Fiona M., Chiecchio, Laura, Dagrada, GianPaolo, Konn, Zoe J., Tapper, William J., Walker, Brian A., Wardell, Christopher P., Gregory, Walter M., Szubert, Alex J., Davies, Faith E. and Morgan, Gareth J. (2011) Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiology Biomarkers & Prevention, 20, (8), 1703-1707. (doi:10.1158/1055-9965.EPI-11-0157). (PMID:21680536).
Full text not available from this repository.
Background: Several cancer types have differences in incidence and clinical outcome dependent on gender, but these are not well described in myeloma. The aim of this study was to characterize gender disparities in myeloma.
Methods: We investigated the association of gender with the prevalence of tumor genetic lesions and the clinical outcome of 1,960 patients enrolled in the phase III clinical trial MRC Myeloma IX. Genetic lesions were characterized by FISH.
Results: Disparities were found in the prevalence of primary genetic lesions with immunoglobulin heavy chain gene (IGH) translocations being more common in women (50% of female patients vs. 38% of male patients, P < 0.001) and hyperdiploidy being more common in men (50% female vs. 62% male, P < 0.001). There were also differences in secondary genetic events with del(13q) (52% female vs. 41% male, P < 0.001) and +1q (43% female vs. 36% male, P = 0.042) being found more frequently in female myeloma patients. Female gender was associated with inferior overall survival (median: 44.8 months female vs. 49.9 months male, P = 0.020).
Conclusions: We found gender-dependent differences in the prevalence of the primary genetic events of myeloma, with IGH translocations being more common in women and hyperdiploidy more common in men. This genetic background may impact subsequent genetic events such as +1q and del(13q), which were both more frequent in women. The higher prevalence of lesions associated with poor prognosis in the female myeloma population, such as t(4;14), t(14;16) and +1q, may adversely affect clinical outcome.
|Digital Object Identifier (DOI):||doi:10.1158/1055-9965.EPI-11-0157|
|Subjects:||R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
|Divisions:||Faculty of Medicine > Human Development and Health
|Date Deposited:||02 May 2012 11:54|
|Last Modified:||31 Mar 2016 14:27|
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)